Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

Over the past several years, we have witnessed a resurgence of interest in the biology and
therapeutic vulnerabilities of small-cell lung cancer (SCLC). This has been driven in part …

Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …

Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history
and dismal prognosis. Given its predisposition for early dissemination, patients are …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique
natural history characterized by a short doubling time, high growth fraction, and early …

Small cell lung cancer (SCLC) is one of the four major histological types of lung cancer. The
incidence of SCLC in developed countries has declined in recent years, presumably …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with clinical and
pathologic characteristics distinct from those of non-SCLC. The primary cause of SCLC is …

Small cell lung cancer (SCLC) arises in peribronchial locations and infiltrates the bronchial
submucosa, including about 15% of lung cancer cases. Despite decades of research, the …